Jané F, Rodríguez de la Serna A
Clinical Pharmacology Department, Universidad Autonoma de Barcelona, Spain.
Eur J Rheumatol Inflamm. 1991;11(4):3-9.
Droxicam acts by inhibition of PGE2 varies. Although it belongs to the oxicam family, it is characterised by being a pro-drug of piroxicam, the molecule undergoing conversion by hydrolysis once dissolved in the digestive tract. This allows us to suppose in principle that, there being less contact between the active drug (piroxicam) and the gastric mucosa, the side effects in the said mucosa would be slight. The studies which have already been performed in healthy volunteers and in patients with osteoarthritis and rheumatoid arthritis, to evaluate the efficacy and the tolerance of droxicam in patients suffering from such clearly inflammatory processes demonstrate an analgesic potential and anti-inflammatory effects which become noticeable after two weeks of treatment, and the drug is well-tolerated.
屈昔康通过抑制前列腺素E2发挥作用。尽管它属于昔康类药物，但它的特点是作为吡罗昔康的前体药物，该分子一旦溶解在消化道中就会通过水解进行转化。这使我们原则上可以推测，活性药物（吡罗昔康）与胃黏膜之间的接触较少，因此在所述黏膜中的副作用会很轻微。已经在健康志愿者、骨关节炎患者和类风湿性关节炎患者中进行的研究，以评估屈昔康在患有此类明显炎症过程的患者中的疗效和耐受性，结果表明其具有镇痛潜力和抗炎作用，在治疗两周后变得明显，并且该药物耐受性良好。
